Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Labeling Problems Targeted In US FDA Budget Request

Executive Summary

Agency seeks legislative authority to update outdated generic drug labels when the reference product has been withdrawn.

Related Content

Cancer Drugs: US FDA Looks Outside For Help On Generic Labeling Updates
CREATES Act: Republican Lawmakers Worry About Frivolous Lawsuits By Generic Firms
US FDA May Ask Congress For More Resources After Withdrawing Generic Label Reg
Project Renewal: US FDA's Plan To Update Generic Cancer Drug Labels Depends On NDA Holders
Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
US FDA's Label Updating Effort Needs Legislation To Impact Generics
US FDA/NORD Partnership Will Further Increase Patient Involvement In Drug Development
Generic Labeling Rule Dies In Latest Reg Agenda, But Electronic Labeling Is Reborn
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts